ھایدرۆکسی پرۆجێسترۆن ھێپتانۆیت

ھایدرۆکسی پرۆجێسترۆن ھێپتانۆیت (OHPH)، ھەروەھا وەک (ھایدرۆکسی پرۆجێسترۆن ئێنانسییەیت hydroxyprogesterone enanthate (OHPEـش ناسراوە، ھەروەھا لەژێر ناوە بازرگانییەکانی (H.O.P) و (Lutogil A.P) و (Lutogyl A.P) لەنێوان ئەوانی تر، دەرمانێکی پرۆجستینە بۆ حاڵەتەکانی پرۆجێستۆجین^[١]^[٢]^[٣]^[٤] بەتەنھا و لەگەڵ تێکەلەی (ئیسترۆجین)، (ئەندرۆجین)، (سترۆییدی ئانابۆلیک) و پرۆجێستۆجینەکانی تریش لە چەنەھا تێکەلەی تریش بەردەستە ناوە بازرگان (تۆکۆجێستان، تریۆئیسترین ڕیتارد، تریۆرمۆن دیپۆستیوم)^[٥]^[٦]^[٧]^[٨]^[٩]^[١٠]^[١١]

سەرچاوەکان

دەروازەی زانست

↑ J. Elks (١٤ی تشرینی دووەمی ٢٠١٤). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. لاپەڕە ٦٦٥–. ژپنک ٩٧٨-١-٤٧٥٧-٢٠٨٥-٣.
↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. کانوونی دووەمی ٢٠٠٠. لاپەڕە ٥٣٢–. ژپنک ٩٧٨-٣-٨٨٧٦٣-٠٧٥-١.
↑ Muller (١٩ی حوزەیرانی ١٩٩٨). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. لاپەڕە ٦١٢–. ژپنک ٩٧٨-٣-٧٦٩٢-٢١١٤-٥.
↑ Axel Kleemann؛ Jürgen Engel (٢٠٠١). Pharmaceutical Substances: Syntheses, Patents, Applications. Thieme. لاپەڕە ١٠٣٣. ژپنک ٩٧٨-٣-١٣-٥٥٨٤٠٤-١.
↑ Axel Kleemann؛ Jürgen Engel (٢٠٠١). Pharmaceutical Substances: Syntheses, Patents, Applications. Thieme. لاپەڕە ١٠٣٣. ژپنک ٩٧٨-٣-١٣-٥٥٨٤٠٤-١.
↑ Sasco AJ، Gendre I، Verbier-Naneix C، Soulier JL، Raffi F، Satgé D، Robert E (١٩٩٨). «Neonatal neuroblastoma and in utero exposure to progestagens». International Journal of Risk and Safety in Medicine. ١١ (2): ١٢١–١٢٨.
↑ Ermiglia، G؛ Valli، P (١٩٥٧). «Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect». Quaderni Clin. Ostet. E Ginecol. ١٢: ٢٨٤–٩٣. Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
↑ Bordier، Philippe (١٩٦٣). «Cure of fifteen osteoporosis cases by a delayed effect of hormonal association». Semaine des Hopitaux. ٣٩ (2): ٨١–٤. ISSN ٠٠٣٧-١٧٧٧. The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
↑ Excerpta medica. Section 8, Neurology and neurosurgery. ١٩٨١. لاپەڕە ١٠.
↑ Testosterone Congeners—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. ٢١ی حوزەیرانی ٢٠١٣. لاپەڕە ١٣٧–. ژپنک ٩٧٨-١-٤٨١٦-٩٢٨٨-٥.
↑ Alberto Frigerio (١٩٨١). Chromatography in Biochemistry, Medicine and Environmental Research: Proceedings of the … International Symposium on Chromatography in Biochemistry, Medicine and Environmental Research. Elsevier Scientific Publishing Company. لاپەڕە ٩٩. ژپنک ٩٧٨-٠-٤٤٤-٤٢٠١٦-٩.

[Elks2014-1] J. Elks (١٤ی تشرینی دووەمی ٢٠١٤). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. لاپەڕە ٦٦٥–. ژپنک ٩٧٨-١-٤٧٥٧-٢٠٨٥-٣.

[IndexNominum2000-2] Index Nominum 2000: International Drug Directory. Taylor & Francis. کانوونی دووەمی ٢٠٠٠. لاپەڕە ٥٣٢–. ژپنک ٩٧٨-٣-٨٨٧٦٣-٠٧٥-١.

[Muller1998-3] Muller (١٩ی حوزەیرانی ١٩٩٨). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. لاپەڕە ٦١٢–. ژپنک ٩٧٨-٣-٧٦٩٢-٢١١٤-٥.

[KleemannEngel2001-4] Axel Kleemann؛ Jürgen Engel (٢٠٠١). Pharmaceutical Substances: Syntheses, Patents, Applications. Thieme. لاپەڕە ١٠٣٣. ژپنک ٩٧٨-٣-١٣-٥٥٨٤٠٤-١.

[KleemannEngel20012-5] Axel Kleemann؛ Jürgen Engel (٢٠٠١). Pharmaceutical Substances: Syntheses, Patents, Applications. Thieme. لاپەڕە ١٠٣٣. ژپنک ٩٧٨-٣-١٣-٥٥٨٤٠٤-١.

[SascoGendre1998-6] Sasco AJ، Gendre I، Verbier-Naneix C، Soulier JL، Raffi F، Satgé D، Robert E (١٩٩٨). «Neonatal neuroblastoma and in utero exposure to progestagens». International Journal of Risk and Safety in Medicine. ١١ (2): ١٢١–١٢٨.

[ErmigliaValli1957-7] Ermiglia، G؛ Valli، P (١٩٥٧). «Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect». Quaderni Clin. Ostet. E Ginecol. ١٢: ٢٨٤–٩٣. Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.

[Bordier1963-8] Bordier، Philippe (١٩٦٣). «Cure of fifteen osteoporosis cases by a delayed effect of hormonal association». Semaine des Hopitaux. ٣٩ (2): ٨١–٤. ISSN ٠٠٣٧-١٧٧٧. The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.

[ExcerptaMedica1981-9] Excerpta medica. Section 8, Neurology and neurosurgery. ١٩٨١. لاپەڕە ١٠.

[ScholarlyEditions2013-10] Testosterone Congeners—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. ٢١ی حوزەیرانی ٢٠١٣. لاپەڕە ١٣٧–. ژپنک ٩٧٨-١-٤٨١٦-٩٢٨٨-٥.

[Frigerio1981-11] Alberto Frigerio (١٩٨١). Chromatography in Biochemistry, Medicine and Environmental Research: Proceedings of the … International Symposium on Chromatography in Biochemistry, Medicine and Environmental Research. Elsevier Scientific Publishing Company. لاپەڕە ٩٩. ژپنک ٩٧٨-٠-٤٤٤-٤٢٠١٦-٩.

[١]

[٢]

[٣]

[٤]

[٥]

[٦]

[٧]

[٨]

[٩]

[١٠]

[١١]